Scholarlink

<p>Few studies have analyzed the prevalence of <i>TERT</i> amplification in thyroid cancer, showing discrepancies in various topics. The impact on tumor recurrence and patient survival in papillary thyroid carcinoma (PTC) remains unknown. Thirteen cancer cell lines and 215 tumor samples from 91 patients, who underwent surgery for PTC (41), poorly differentiated thyroid carcinoma (PDC = 15), or anaplastic thyroid carcinoma (ATC = 35), were analyzed. Clonality, spread with tumor dedifferentiation or metastatic PTC cells, and coexistence with <i>TERTp</i>, <i>BRAF</i>, <i>RAS</i>, and <i>PIK3CA</i> mutations were also investigated. <i>TERT</i> amplification was found in 17%, 20%, and 17% of the PTC, PDC, and ATC, respectively. It was more frequent in follicular variant PTC and PTC with distant metastases (86%, <i>P</i> = 0.0448). The cell lines HTh74, SW1736, and T242 had amplification. In PTC, <i>TERT</i> amplification was a subclonal event. The increase in <i>TERT</i> copy number spread in all cases with metastatic PTC cells. In 67% of the PDC and 100% of the ATC, <i>TERT</i> activation segregated with tumor dedifferentiation. <i>TERT</i> amplification correlated with <i>TERTp</i> mutations in PTC (<i>P</i> = 0.0313) and <i>PIK3CA</i> mutations in ATC (<i>P</i> = 0.0272). <i>TERT</i> amplification significantly correlated with vascular invasion (<i>P</i> = 0.03637), distant metastases at diagnosis and/or follow-up (<i>P</i> = 0.04482), metachronous distant metastases (<i>P</i> = 0.03131), death patient status (<i>P</i> = 0.000829), stage at diagnosis (<i>P</i> = 0.01995), and stage III/IV at last follow-up (<i>P</i> = 0.01552). <i>TERT</i> amplification associated independently with tumor-related recurrence and death. Our study shows that PTC can be stratified into clinically prognostic relevant categories based on the presence or not of <i>TERT</i> amplification in the cells.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

TERT Amplification a Risk Stratification Marker in Papillary Thyroid Carcinoma, Significantly Correlated with Tumor Recurrence and Survival

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月24日

查看全文
  • Sara Gil-Bernabé,
  • Noa Feás-Rodríguez,
  • Enrique Pérez-Riesgo,
  • Miriam Corraliza-Gómez,
  • Joaquín Fra Rodríguez,
  • Ginesa García-Rostán

摘要

Few studies have analyzed the prevalence of TERT amplification in thyroid cancer, showing discrepancies in various topics. The impact on tumor recurrence and patient survival in papillary thyroid carcinoma (PTC) remains unknown. Thirteen cancer cell lines and 215 tumor samples from 91 patients, who underwent surgery for PTC (41), poorly differentiated thyroid carcinoma (PDC = 15), or anaplastic thyroid carcinoma (ATC = 35), were analyzed. Clonality, spread with tumor dedifferentiation or metastatic PTC cells, and coexistence with TERTp, BRAF, RAS, and PIK3CA mutations were also investigated. TERT amplification was found in 17%, 20%, and 17% of the PTC, PDC, and ATC, respectively. It was more frequent in follicular variant PTC and PTC with distant metastases (86%, P = 0.0448). The cell lines HTh74, SW1736, and T242 had amplification. In PTC, TERT amplification was a subclonal event. The increase in TERT copy number spread in all cases with metastatic PTC cells. In 67% of the PDC and 100% of the ATC, TERT activation segregated with tumor dedifferentiation. TERT amplification correlated with TERTp mutations in PTC (P = 0.0313) and PIK3CA mutations in ATC (P = 0.0272). TERT amplification significantly correlated with vascular invasion (P = 0.03637), distant metastases at diagnosis and/or follow-up (P = 0.04482), metachronous distant metastases (P = 0.03131), death patient status (P = 0.000829), stage at diagnosis (P = 0.01995), and stage III/IV at last follow-up (P = 0.01552). TERT amplification associated independently with tumor-related recurrence and death. Our study shows that PTC can be stratified into clinically prognostic relevant categories based on the presence or not of TERT amplification in the cells.